What metformin does in the body

Metformin is a medication that lowers blood sugar by reducing the amount of glucose your liver produces and by making your cells more responsive to insulin. It has been used for decades to treat type 2 diabetes, and in recent years researchers have begun studying whether it might slow aging or extend lifespan in people without diabetes.

The drug works through several mechanisms. It activates an enzyme called AMPK, which plays a role in cellular energy management. It also affects how your mitochondria—the power plants of your cells—function, and it may reduce inflammation. These pathways are involved in aging, which is why scientists became interested in testing metformin outside of diabetes treatment.

Metformin is taken by mouth, usually in doses of 500 to 2,000 mg per day split into multiple doses. Your body does not metabolize it; instead, your kidneys filter it out unchanged. This is why kidney function matters for safety—if your kidneys cannot clear the drug efficiently, it can build up to harmful levels.

Key Takeaways

  • Metformin lowers blood sugar by reducing glucose production in the liver and improving how cells respond to insulin, mechanisms that may also affect aging pathways.
  • Human studies in people without diabetes are still ongoing; most evidence for longevity effects comes from animal studies and observational data, not controlled trials.
  • The most common side effect is gastrointestinal upset, which often improves if you take the drug with food or start at a lower dose.
  • Metformin requires kidney function to be safe, and it can interfere with vitamin B12 absorption over time, so monitoring is necessary.
  • A major clinical trial called TAME is currently testing whether metformin delays aging in older adults without diabetes, with results expected in the coming years.

What animal and observational studies suggest

In mice and other laboratory animals, metformin has extended lifespan and improved markers of aging, including muscle strength, cognitive function, and resistance to stress. These studies are the reason metformin attracted attention as a potential longevity compound. However, animal studies do not always translate to humans, and the doses used in mice are often much higher relative to body weight than doses people take.

Observational studies in humans—which track people over time without randomly assigning them to take the drug—have found that people with diabetes who take metformin live longer on average than people with diabetes who take other medications. This is a real finding, but it does not prove metformin caused the longer lifespan. People who tolerate metformin well may be healthier overall, or they may be more likely to follow medical information, both of which could explain the difference.

A few small human studies have looked at metformin's effects on aging markers in people without diabetes. These have found changes in some measures—for example, improvements in insulin sensitivity and reductions in inflammation—but the studies were short and involved small numbers of people. They do not show whether these changes translate to living longer.

The TAME trial and what it will measure

The TAME trial (Targeting Aging with Metformin) is a large, randomized controlled study now underway in the United States. It is enrolling older adults without diabetes and randomly assigning them to take metformin or a placebo for about six years. The primary outcome is whether metformin delays the onset of age-related diseases—heart disease, cancer, cognitive decline, and physical disability—rather than whether it extends lifespan directly.

TAME is being conducted by the American Federation for Aging Research and is funded by the National Institutes of Health. Results are expected in the mid-to-late 2020s. This trial will be the first large, well-controlled test of metformin's effects on aging in humans, and it will either support or undermine the case for using metformin as a longevity drug in people without diabetes.

Until TAME results are available, any claim that metformin extends human lifespan or prevents age-related disease remains unproven. The evidence is suggestive enough that researchers think it is worth testing, but not strong enough to recommend the drug for this purpose outside of a clinical trial.

Side effects and who should not take it

The most common side effect is gastrointestinal upset—nausea, diarrhea, or stomach pain—which occurs in about 30% of people who start metformin. This often improves within a few weeks, especially if you take the drug with food or start at a lower dose and increase gradually. Extended-release formulations cause fewer digestive problems than when ready-release versions.

A more serious but rare side effect is lactic acidosis, a buildup of lactate in the blood that can be life-threatening. This is why metformin is not recommended for people with severe kidney disease, liver disease, or acute illness. Your doctor will check your kidney function before prescribing metformin and periodically while you take it.

Metformin can also interfere with vitamin B12 absorption over time, leading to deficiency in some people. If you take metformin long-term, your doctor may monitor your B12 levels or recommend a supplement. Metformin is generally not recommended during pregnancy because its safety in pregnancy is not well established.

How metformin compares to other compounds in this category

Metformin is unique among emerging longevity compounds because it has a long track record of safe use in millions of people with diabetes. Most other compounds in this category—rapamycin, NAD+ boosters, senolytics—have been studied far less in humans and have less established safety profiles. This makes metformin a natural starting point for longevity research.

However, metformin's mechanism is also narrower than some alternatives. It primarily affects glucose metabolism and AMPK signaling, whereas compounds like rapamycin target mTOR, a different aging pathway. Some researchers believe a combination approach might be more effective than any single drug, but this has not been tested in humans.

Metformin is also inexpensive—a month's supply costs a few dollars—which is another reason it has become the focus of large trials like TAME. Compounds that are expensive or difficult to manufacture are less likely to be tested in large populations.

Current evidence for specific health outcomes

In people with diabetes, metformin clearly reduces the risk of heart disease and death compared to other diabetes medications. In people without diabetes, the evidence is much weaker. A few small studies have found that metformin may improve cholesterol levels, reduce inflammation markers, and improve insulin sensitivity, but these studies were short and involved small groups.

For cancer, the picture is mixed. Some observational studies suggest metformin may lower cancer risk, but others find no effect. Animal studies show metformin can slow tumor growth in some models, but this does not necessarily mean it prevents cancer in humans. The TAME trial will test whether metformin reduces cancer incidence, which will be important evidence.

For cognitive function and dementia, there is almost no human evidence. A few animal studies suggest metformin might protect against cognitive decline, but no large human trials have tested this. This is another question TAME may help answer.

Frequently Asked Questions

Can I take metformin if I don't have diabetes?

Metformin is approved by the FDA only for type 2 diabetes treatment. Taking it without diabetes is off-label use, meaning a doctor can prescribe it but it is not the drug's official indication. Some doctors do prescribe metformin off-label for people at high risk of diabetes or for other reasons, but this is not standard practice and is not recommended outside of research trials like TAME.

How long would I need to take metformin to see longevity benefits?

This is unknown. The TAME trial is running for about six years, which researchers believe is long enough to detect differences in disease onset, but it is possible that longer use would be needed to see effects on lifespan itself. Animal studies suggest benefits accumulate over time, but there is no data on the minimum duration in humans.

Does metformin interact with other medications?

Metformin has relatively few serious drug interactions, but it can interact with contrast dye used in some imaging procedures and with certain medications that affect kidney function. If you take metformin, tell your doctor about all other medications and supplements you use, and inform any imaging center before a procedure.

What happens if I stop taking metformin?

If you stop metformin, any blood sugar-lowering effect disappears within days. If you were taking it for diabetes, your blood sugar will rise again. If you were taking it off-label for potential longevity effects, any benefits would likely reverse, though this has not been formally studied.

Is metformin the same as a low-carb diet?

No. Both metformin and a low-carb diet improve insulin sensitivity and lower blood sugar, but they work through different mechanisms. Metformin acts on the liver and cells; a low-carb diet reduces the amount of glucose entering the bloodstream. They can be combined, and some research suggests they may work better together than either alone.